首页> 外文期刊>Clinical Rheumatology >The determination of matrix metalloproteinase 9 activity and gene expression levels in Behcet’s disease patients with aneurysmal complications
【24h】

The determination of matrix metalloproteinase 9 activity and gene expression levels in Behcet’s disease patients with aneurysmal complications

机译:白塞特病合并动脉瘤的患者基质金属蛋白酶9活性和基因表达水平的测定

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The information concerning aneurysmal progress in Behcet’s disease is still insufficient, while researches in the role of matrix metalloproteinases (MMPs) in aneurysmal formation are rapidly expanding. The goal of the present study is to investigate the role of metalloproteinase 9 (MMP-9) in vascular complications which is observed in 10% of Behcet’s disease patients. Three groups have been studied; patients with Behcet’s disease, patients with Behcet’s disease who have vascular problems (vasculo-Behcet’s), and patients with abdominal aortic aneurysm (AAA). The third group was used as a control. The activity and gene expression levels of MMP-9 in plasma have been determined. We showed that compared to AAA patients there was no difference in the MMP-9 activity in Behcet’s disease patients (vascular and non-vascular). We also evaluated the gene expression level and activity of MMP-9 for every patient. The increase in the gene expression level for MMP-9 could only be detected at two patients. One of them was Behcet’s, the other was AAA patient. It is surprising that MMP levels of these patients were different. While the patient with Behcet’s had low protein level, another patient with AAA had high of MMP-9 level. This result suggested to us that the relationship between gene expression and active protein level is not correlated. It is not sufficient alone to determine MMPs levels for evaluating the pathogenesis. At the same time gene expression and the level of active protein should be assessed together.
机译:关于Behcet病的动脉瘤进展的信息仍然不足,而关于基质金属蛋白酶(MMP)在动脉瘤形成中的作用的研究正在迅速扩展。本研究的目的是研究金属蛋白酶9(MMP-9)在血管并发症中的作用,在10%的Behcet病患者中观察到。研究了三组。 Behcet病患者,患有血管问题的Behcet病患者(血管-Behcet病)以及腹主动脉瘤(AAA)。第三组用作对照。已经确定了血浆中MMP-9的活性和基因表达水平。我们证明,与AAA患者相比,Behcet病患者(血管和非血管)的MMP-9活性没有差异。我们还评估了每个患者的MMP-9的基因表达水平和活性。仅在两名患者中检测到MMP-9的基因表达水平增加。其中一个是Behcet,另一个是AAA患者。令人惊讶的是,这些患者的MMP水平不同。 Behcet病人的蛋白质水平低,而另一位AAA病人的MMP-9水平高。该结果向我们表明,基因表达与活性蛋白水平之间的关系不相关。仅仅确定用于评估发病机理的MMP水平是不够的。同时,应该一起评估基因表达和活性蛋白水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号